Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Dermatologic 1

Conditions

Melanoma 7Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Stomach Neoplasms 5Pancreatic Neoplasms 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Neoplasms 4Nasopharyngeal Carcinoma 4Neoplasm Metastasis 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Adenocarcinoma 1Solid Tumors 1Solid Tumor, Adult 1Solid Tumor 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × spartalizumab × 1 year × Clear all
NCT03568058 2026-03-24

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

University of California, San Diego

Phase 1 Completed
25 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT06547957 2025-08-13

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

iTeos Therapeutics

Phase 1 Active not recruiting
55 enrolled
Tumor-Agnostic

Neoplasms

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Dermatologic

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡